痴呆患者中潜在高风险抗精神病药使用:全国数据链接研究
该研究基于澳大利亚2021年人口普查与药品福利计划链接数据,纳入22710名≥65岁使用抗精神病药的痴呆患者,发现86.2%存在至少一项潜在高风险用药指标。最常见为合并精神药物(77.3%),其次为药物相互作用(31.1%)、药物-疾病相互作用(22.6%)和长期使用(9.4%)。
要点
- 86.2%的痴呆抗精神病药使用者存在至少一项高风险用药指标。
- 合并精神药物最常见(77.3%),长期使用最少见(9.4%)。
- 高龄、高教育、偏远地区与较低风险相关,多病与较高风险相关。
核心结论
- 痴呆患者抗精神病药使用中潜在高风险情况普遍,近九成使用者存在至少一项高风险指标,优化用药仍具挑战。
研究设计与样本
- 回顾性横断面研究,使用2021年澳大利亚人口普查与药品福利计划国家链接数据,纳入22710名≥65岁使用抗精神病药的痴呆患者。
主要发现
- 9947人(43.8%)使用利培酮;19576人(86.2%)存在至少一项高风险指标。
- 合并精神药物17560人(77.3%),药物相互作用7059人(31.1%),药物-疾病相互作用5125人(22.6%),长期使用2129人(9.4%)。
- ≥75岁、较高教育程度和居住在偏远地区与至少一项指标风险较低相关,多病与风险增加相关。
- 居住于非私人住宅和多位处方者与多项指标风险较高相关(药物-疾病相互作用除外)。
- 文化语言多样化人群药物-疾病相互作用风险较高但合并精神药物风险较低。
关键数值与推荐
- 长期使用定义为2021年8月1日起6个月内≥4次抗精神病药处方。
- 药物-疾病相互作用指卒中或糖尿病。
- 高风险指标包括药物相互作用、药物-疾病相互作用、合并精神药物和长期使用四类。
临床怎么用
- 对痴呆患者处方抗精神病药时应常规评估药物相互作用、合并精神药物及长期使用风险。
- 关注多病、多位处方者及非私人住宅居住者等高风险管理,减少不必要的精神药物联合使用。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the prevalence of and sociodemographic factors associated with potentially high-risk antipsychotic use in people living with dementia in Australia. DESIGN: Retrospective cross-sectional study using national linked data from the 2021 Census and the Pharmaceutical Benefits Scheme. SETTING AND PARTICIPANTS: All people aged ≥65 years who responded to the 2021 Census, self-reported a diagnosis of dementia and/or were dispensed an acetylcholinesterase inhibitor or memantine, and purchased ≥1 antipsychotic subsidized by the Pharmaceutical Benefits Scheme between August 1, 2021, and October 31, 2021, were included. METHODS: Four measures of potentially high-risk antipsychotic use were assessed: possible drug-drug interactions, possible drug-disease interactions (DDSIs) (ie, stroke or diabetes), concomitant psychotropic medication (CPM), and prolonged duration of use (ie, ≥4 prescriptions in the 6 months from August 1, 2021). Factors associated with each measure were identified by logistic regression models. RESULTS: Of the 22,710 individuals using at least 1 antipsychotic, 9947 (43.8%) were using risperidone. A total of 19,576 people (86.2%) had ≥1 measure of high-risk use. The most common measure was CPM (n = 17,560, 77.3%), followed by drug-drug interaction (n = 7059, 31.1%), DDSI (n = 5125, 22.6%), and prolonged duration of use (n = 2129, 9.4%). The factors of aged ≥75 years, higher educational attainment, and living in a remote area were associated with lower odds of having ≥1 measure, whereas multimorbidity was associated with increased likelihood. Residing in nonprivate dwellings and having multiple prescribers were associated with higher odds of having multiple measures, except for DDSI. Culturally and linguistically diverse populations had higher odds of DDSI but lower odds of CPM. CONCLUSIONS AND IMPLICATIONS: Achieving quality use of antipsychotics in individuals with dementia remains challenging, with almost 9 of 10 antipsychotic users having at least 1 measure of high-risk use. Future research should investigate strategies to optimize antipsychotic use in people living with dementia and target subgroups at higher risk.
引用
- Le HT, Lau ECY, Ali MA, et al. Potentially High-Risk Antipsychotic Use in People With Dementia: A National Data Linkage Study. J Am Med Dir Assoc. 2025. PMID: 40690946. doi:10.1016/j.jamda.2025.105750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。